Gilead initiates two studies of remdesivir in UK

2 April 2020 (Last Updated April 2nd, 2020 14:30)

Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.

The two studies will be conducted at 15 sites in the country, primarily in England and Scotland.

One of the trials will involve patients with moderate symptoms and the other will enrol patients in a serious condition.

Read the full article here